# Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

> **NCT01157871** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 36 (actual)

## Conditions studied

- Peripheral Arterial Occlusive Disease

## Interventions

- **DRUG:** XRP0038 (NV1FGF)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01157871
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2010-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157871, "Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01157871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*